Login to Your Account

BIO 2011

Pay Now or Pay Later? Don't Ignore Importance of Phase II

By Jennifer Boggs

Wednesday, June 29, 2011
WASHINGTON – For drug development firms trying to save money or playing catch-up in a highly competitive field, it might seem a good idea to skimp on Phase II testing by enrolling fewer patients, conducting only one midstage study or even leapfrogging straight to Phase III and hoping that the efficacy signal observed in Phase I wasn't just a fluke.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription